180 Life Sciences jumps as hand deformity therapy meets study main goals

Forum Markets,

06/12/2021 14:00

** Shares of biotech co  ATNF.O  jump ~10% at $3.60
premarket 
    ** Co provides positive follow-up information on interim
data from mid-stage study of its drug candidate, adalimumab,
being evaluated with partner Oxford University for Dupuytren's
disease  urn:newsml:reuters.com:*:nGNX8wW8zc 
    ** Dupuytren's disease is a hand deformity that usually
develops over the years, affecting a layer of tissue that lies
under the skin of the palm
    ** ATNF CEO says the study achieved the main goals "by
significantly diminishing the hardness and size of the
Dupuytren’s nodules"
    ** Co plans to have an initial meeting with the U.S. FDA and
UK’s health regulatory body in H1 2022
    ** Up to Friday's close, stock had risen 19.78% YTD 
    
    

 (Reporting by Oishee Majumdar in Bengaluru)
 ((oishee.majumdar@thomsonreuters.com;))